$ARTV

2 theses

bullish 50%neutral 0%bearish 50%

Avg return (1y)

—

Win rate (1y)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Nov 2, 4:15 PM ET

$ARTVSEC Form 4bearish

Aslan Fred · Chief Executive Officer at Artiva Biotherapeutics, Inc. · 27d agono track record yet

Sold 61,696 @ $6.84 avg · $421,828 · 2026-10-05

Form 4: Aslan Fred sold ARTV

Aslan Fred (Chief Executive Officer at Artiva Biotherapeutics, Inc.) reported an open-market sale of 61,696 shares of ARTV at an average $6.84, roughly $421,828, in a Form 4 filed 2026-10-06.

At post $7.27Now $4.19-42.4% since postedas of Nov 2, 4:15 PM ET

1d-3.7%

3d-4.5%

1w-13.5%

1m—

3m—

6m—

1y—

View filing on SEC.gov →

$ARTVr/pennystocksBullishbullish

u/StockyJ122 · 323d ago2 prior · 0% at 3mo

Wedbush says ARTV will jump to $23 (it's less than $3.5 now) — An interesting play for tomorrow

Wedbush analyst sees compelling setup with early clinical validation, accelerating enrollment in Ph 2a basket trial for RA and multiple indications (Sjögren's, myositis, scleroderma), regulatory support, and substantial cash cushion. Analyst rates Outperform with $23 price target (~600% upside) citing near-term appreciation potential from key data and regulatory events.

At post $6.30Now $4.19-33.5% since postedas of Nov 2, 4:15 PM ET

1d—

3d-31.4%

1w-24.8%

1m-27.0%

3m-1.9%

6m+35.6%

1y—

original post →

End of results.